BIOMARKER:

APOBEC mutagenesis

News alerts, weekly reports and conference planners

APOBEC mutagenesis	Urothelial Cancer	APOBEC mutagenesis	Urothelial Cancer	atezolizumab Sensitive: B - Late Trials atezolizumab Sensitive : B	atezolizumab Sensitive: B - Late Trials atezolizumab Sensitive : B
APOBEC mutagenesis	Urothelial Cancer	APOBEC mutagenesis	Urothelial Cancer	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3
APOBEC mutagenesis	Urothelial Cancer	APOBEC mutagenesis	Urothelial Cancer	cisplatin Resistant: C3 – Early Trials cisplatin Resistant : C3	cisplatin Resistant: C3 – Early Trials cisplatin Resistant : C3
APOBEC mutagenesis	Urothelial Cancer	APOBEC mutagenesis	Urothelial Cancer	carboplatin Resistant: C3 – Early Trials carboplatin Resistant : C3	carboplatin Resistant: C3 – Early Trials carboplatin Resistant : C3

Associations